FSH: Which Tests to Order Alongside for a Complete Hormonal Picture

Why a Standalone FSH Result Is Not Enough

FSH (follicle-stimulating hormone) is a pituitary glycoprotein that drives follicular development in women and spermatogenesis in men. A single FSH value without companion markers is like reading one vital sign and skipping the rest. The 2020 Endocrine Society clinical practice guideline on primary ovarian insufficiency explicitly recommends pairing FSH with estradiol on two separate occasions before confirming a diagnosis [1]. The same principle applies across every clinical scenario where FSH is ordered.

FSH fluctuates across the menstrual cycle, across the day, and even between consecutive blood draws. In one study published in the Journal of Clinical Endocrinology & Metabolism, intra-individual FSH coefficient of variation reached 20-30% between cycles in women over 40 [2]. Without estradiol and LH drawn from the same sample, an isolated FSH of 18 IU/L could indicate early perimenopause, a mid-cycle surge, or lab noise. Context collapses ambiguity into diagnosis.

The cost argument for skipping companion tests does not hold up either. Adding LH and estradiol to an FSH order typically adds $30-60 at commercial lab pricing and can prevent an entire additional visit for repeat testing.

The Core Trio: FSH, LH, and Estradiol

Every FSH order should include LH and estradiol at minimum. This trio forms the interpretive backbone for reproductive endocrinology. LH and FSH are both gonadotropins released by the anterior pituitary, but their ratio and absolute levels point in different diagnostic directions.

An FSH of 35 IU/L with an LH of 28 IU/L and estradiol below 20 pg/mL points toward ovarian failure or menopause. The same FSH of 35 with an estradiol of 200 pg/mL suggests the sample was drawn near ovulation, not during the early follicular phase. The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 141 on management of menopausal symptoms recommends using FSH and estradiol together, drawn in the early follicular phase, to evaluate menopausal status in women aged 40-45 with irregular cycles [3].

An LH:FSH ratio greater than 2:1 in a woman with oligomenorrhea and hyperandrogenism supports a PCOS diagnosis per the Rotterdam criteria. A 2016 meta-analysis in Human Reproduction Update (N=4,297) found that LH:FSH ratio >2 had 60% sensitivity and 91% specificity for PCOS when combined with ultrasound findings [4]. Without the LH, the FSH alone would show a normal or low-normal value and miss the pattern entirely.

Fertility Workup: The Day 2-4 Panel

For women undergoing fertility evaluation, the Endocrine Society and American Society for Reproductive Medicine (ASRM) recommend a cycle day 2-4 panel that includes FSH, estradiol, LH, and AMH [5]. Each test answers a different question.

FSH on day 3 reflects pituitary drive. A value above 10 IU/L suggests diminished ovarian reserve. Estradiol drawn simultaneously must be below 60-80 pg/mL for the FSH to be interpretable. An elevated day-3 estradiol can suppress FSH through negative feedback, masking a truly elevated value. This is one of the most common misinterpretation traps in reproductive endocrinology.

AMH is cycle-independent and reflects the antral follicle pool directly. A 2019 Cochrane review found AMH was a better predictor of poor ovarian response to stimulation than basal FSH (area under the curve 0.78 vs. 0.69) [6]. AMH below 1.0 ng/mL combined with FSH above 10 IU/L paints a much clearer picture of diminished reserve than either test alone.

TSH belongs on every fertility panel. The American Thyroid Association recommends TSH screening for all women planning pregnancy, with a target of <2.5 mIU/L in the first trimester [7]. Subclinical hypothyroidism (TSH 4.5-10 mIU/L) can raise prolactin, disrupt GnRH pulsatility, and raise FSH indirectly. Correcting thyroid function sometimes normalizes an apparently abnormal FSH.

Add prolactin if cycles are irregular or absent. Hyperprolactinemia suppresses GnRH and can produce a falsely low FSH. A prolactin above 100 ng/mL warrants pituitary MRI regardless of FSH level.

Perimenopause and Menopause Confirmation

The 2022 North American Menopause Society (NAMS) position statement notes that menopause is a clinical diagnosis in women over 45 with 12 months of amenorrhea, and lab testing is not required in that scenario [8]. Lab confirmation becomes necessary in three situations: women aged 40-45 with menstrual irregularity, women who have had a hysterectomy (no periods to track), and women on hormonal contraception that masks cycle changes.

For these patients, the recommended approach is FSH plus estradiol drawn on two separate occasions, 4-6 weeks apart. FSH consistently above 25-30 IU/L with estradiol below 50 pg/mL supports the diagnosis. A single elevated FSH does not confirm perimenopause. The Endocrine Society guideline on primary ovarian insufficiency uses an even higher threshold: two FSH values above 40 IU/L at least one month apart for women under 40 [1].

Inhibin B is an optional add-on in this setting. Produced by ovarian granulosa cells, inhibin B drops before FSH rises during the menopausal transition. A 2008 study in the Journal of Clinical Endocrinology & Metabolism (N=436, Penn Ovarian Aging Study) found inhibin B declined below 35 pg/mL approximately 4 years before the final menstrual period [9]. It can flag the transition earlier than FSH alone, though most clinicians reserve it for research settings.

Male Hypogonadism: The Complete Panel

FSH in men reflects Sertoli cell function and spermatogenesis. The Endocrine Society 2018 guideline on testosterone therapy in men with hypogonadism recommends checking FSH and LH only after confirming low total testosterone on two morning draws [10]. The sequence matters. Total testosterone comes first.

Once low testosterone is confirmed, the paired panel includes:

• FSH and LH to distinguish primary (testicular) from secondary (pituitary/hypothalamic) hypogonadism. Primary: FSH and LH elevated. Secondary: FSH and LH low or inappropriately normal.
• Prolactin to screen for prolactinoma, the most common pituitary tumor. Dr. Bradley Anawalt, an endocrinologist at the University of Washington, has noted: "A prolactin level should be obtained in every man with secondary hypogonadism because prolactinomas are eminently treatable and missing one has real consequences" [10].
• Total and free testosterone (drawn before 10 AM) as the primary diagnostic measure.
• SHBG (sex hormone-binding globulin) if total testosterone is borderline, because obesity, diabetes, and liver disease alter SHBG and can make total testosterone misleading.

An FSH above 12 IU/L with low testosterone points to primary testicular failure. An FSH below 2 IU/L with low testosterone suggests secondary hypogonadism and warrants pituitary imaging. The American Urological Association (AUA) 2018 guideline on male infertility recommends semen analysis alongside FSH in men presenting with infertility, as FSH above 7.6 IU/L predicted abnormal spermatogenesis with 87% sensitivity in a cohort of 1,052 men [11].

Pituitary Function: When to Go Beyond Gonadotropins

If FSH is unexpectedly low (below 1.5 IU/L in a reproductive-age adult) or if LH and FSH are both suppressed without an obvious cause like hormonal contraception, the differential includes pituitary pathology. A comprehensive anterior pituitary panel adds:

• Morning cortisol (drawn at 8 AM). Values below 3 mcg/dL suggest adrenal insufficiency, possibly from ACTH deficiency. Values above 15 mcg/dL generally exclude it.
• Free T4 and TSH to assess the thyroid axis. Central hypothyroidism shows low free T4 with a normal or low TSH.
• IGF-1 as a screen for growth hormone deficiency. In adults, GH deficiency co-occurs with gonadotropin deficiency in approximately 75% of patients with panhypopituitarism [12].
• Prolactin to detect pituitary stalk compression or prolactinoma. Mild elevations (25-100 ng/mL) may indicate stalk effect from a non-functioning adenoma. Levels above 200 ng/mL are highly specific for prolactinoma.

The Endocrine Society 2016 guideline on pituitary incidentalomas recommends full anterior pituitary hormone testing for any pituitary mass larger than 6 mm [12]. An isolated low FSH can be the first clue that a broader pituitary evaluation is needed.

PCOS Evaluation: The Ratio and Its Supporting Cast

In women with suspected PCOS, FSH and LH together form one arm of the diagnostic workup. The Rotterdam criteria require two of three features: oligo-anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound. FSH is typically normal or low in PCOS, while LH is disproportionately elevated.

The supporting panel includes:

• Total and free testosterone to document hyperandrogenism. A 2018 Endocrine Society guideline on PCOS recommends measuring total testosterone and calculating free testosterone using SHBG, rather than relying on direct free testosterone assays, which are often inaccurate [13].
• DHEA-S if testosterone is markedly elevated, to rule out adrenal sources.
• 17-hydroxyprogesterone drawn in the early morning follicular phase to screen for non-classic congenital adrenal hyperplasia (NCCAH). NCCAH mimics PCOS in up to 4-6% of hyperandrogenic women, and a morning 17-OHP above 200 ng/dL warrants cosyntropin stimulation testing [13].
• TSH and prolactin to exclude thyroid disease and hyperprolactinemia, which can both produce menstrual irregularity and mimic PCOS.
• Fasting glucose and insulin or HbA1c, since PCOS carries a 5-8x increased risk of type 2 diabetes per AACE/ACE guidelines [14].

Timing and Sample Collection: Getting It Right

The best panel in the world produces garbage data if drawn at the wrong time. Specific timing rules for FSH-inclusive panels:

Premenopausal women: Draw FSH, LH, and estradiol on cycle day 2, 3, or 4. Day 3 is conventional but days 2-4 are acceptable per ASRM guidance. Drawing after day 5 introduces mid-follicular estradiol rises that distort results.

Men: Draw all hormones before 10 AM after an overnight fast. Testosterone has a diurnal rhythm with peak levels in the morning. FSH is less diurnal but standardizing the draw time improves reproducibility.

Postmenopausal women and women on continuous hormonal contraception: Timing within the day is less critical, but morning fasting draws are still preferred for consistency.

Biotin interference: High-dose biotin supplementation (5-10 mg/day, common in hair and nail supplements) can interfere with streptavidin-biotin immunoassays used for FSH, TSH, and estradiol. The FDA issued a safety communication in 2017 warning that biotin interference caused falsely normal TSH in a patient with Graves' disease [15]. Patients should stop biotin at least 72 hours before hormone testing.

How FSH Fits Into HealthRX Telehealth Panels

Patients ordering labs through HealthRX for hormone-therapy evaluation receive FSH as part of broader panels rather than as a standalone test. A female perimenopause/HRT evaluation panel typically bundles FSH, LH, estradiol, progesterone, TSH, free T4, and a complete metabolic panel. A male TRT evaluation includes total testosterone, free testosterone, FSH, LH, estradiol, prolactin, CBC, lipid panel, PSA (for men over 40), and a comprehensive metabolic panel.

This bundled approach ensures no critical companion test is missed and eliminates the need for repeat blood draws. If your initial FSH result raises questions, your HealthRX clinician can add AMH, DHEA-S, inhibin B, or pituitary imaging based on the pattern that emerges from the complete panel.

Interpreting FSH in Clinical Context

FSH values only make sense within a clinical framework. A quick reference for pattern recognition:

High FSH (above 25 IU/L in women, above 12 IU/L in men) with low estradiol or testosterone indicates primary gonadal failure. In women, this is premature ovarian insufficiency (if under 40) or menopause (if over 40). In men, it points to primary testicular failure from Klinefelter syndrome, prior chemotherapy, or cryptorchidism.

Low FSH (below 1.5 IU/L) with low sex steroids indicates secondary hypogonadism from pituitary or hypothalamic dysfunction. Causes include pituitary adenoma, infiltrative disease, prior radiation, severe caloric restriction, or high-dose opioid use.

Normal FSH with abnormal LH (LH:FSH ratio >2) in a woman with oligomenorrhea suggests PCOS. In a man, an isolated LH elevation with normal FSH and borderline-low testosterone may indicate early Leydig cell dysfunction while Sertoli cell function is preserved.

Elevated FSH with normal semen analysis in a man is a compensated state. Sertoli cells are working harder under increased FSH drive to maintain adequate sperm production. This does not require treatment but warrants monitoring.

The Endocrine Society's 2019 guideline on female infertility specifies that day-3 FSH above 10 IU/L (with estradiol below 60 pg/mL) is associated with reduced ovarian reserve and lower IVF success rates, though it does not predict natural conception as reliably [5].

When to Recheck FSH and Its Companion Tests

Repeat testing intervals depend on the clinical scenario. For fertility monitoring, repeat the day-3 FSH/estradiol/AMH panel every 6-12 months if initial values were borderline. For perimenopause confirmation, draw the second FSH/estradiol pair 4-6 weeks after the first. For men on testosterone replacement therapy, FSH will drop (often to undetectable levels) because exogenous testosterone suppresses GnRH. Recheck FSH and LH 3 months into TRT to confirm pituitary suppression. If FSH remains elevated on TRT, consider medication adherence issues or an FSH-secreting pituitary adenoma, which is rare but real.

Patients on clomiphene citrate for secondary hypogonadism should see FSH rise into the 4-12 IU/L range. Check FSH, LH, and total testosterone 4-6 weeks after starting therapy to confirm response. Patients prescribed letrozole for ovulation induction should have FSH monitored with transvaginal ultrasound during stimulation cycles per ASRM protocols [5].

A baseline FSH drawn with appropriate companion tests and correct timing gives you a diagnostic map. Without those companions, it gives you a number on a page.